RHJA
KITE

Rice Hall James & Associates’s Kite Pharma, Inc. KITE Stock Holding History

Rice Hall James & Associates’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-57,682
Closed -$5.98M – 308
2017
Q2 		$5.98M Buy
57,682
+11,840
+26% +$966K 0.26% 96
2017
Q1 		$3.6M Buy
45,842
+440
+1% +$27.2K 0.18% 106
2016
Q4 		$2.04M Sell
45,402
-811
-2% -$39.8K 0.1% 188
2016
Q3 		$2.58M Buy
46,213
+5,212
+13% +$290K 0.13% 142
2016
Q2 		$2.05M Buy
41,001
+580
+1% +$28.5K 0.12% 168
2016
Q1 		$1.86M Buy
40,421
+876
+2% +$42.4K 0.11% 181
2015
Q4 		$2.44M Buy
39,545
+16,820
+74% +$1.18M 0.14% 138
2015
Q3 		$1.26M Buy
+22,725
New +$1.43M 0.08% 221

Other funds holding KITE

CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Rice Hall James & Associates's KITE Position: Q3 2017 in Review

Rice Hall James & Associates sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 57,682 shares — an estimated $5.98M sold.

Rice Hall James & Associates first reported a position in KITE in Q3 2015 and held it in 8 quarters. The position peaked at $5.98M in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

  • Rice Hall James & Associates reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Rice Hall James & Associates sold 57,682 Kite Pharma, Inc. shares in Q3 2017, an estimated $5.98M.
  • Rice Hall James & Associates first reported a position in Kite Pharma, Inc. in Q3 2015 and held it in 8 quarters.
  • Rice Hall James & Associates's Kite Pharma, Inc. position peaked at $5.98M in Q2 2017.
  • 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Rice Hall James & Associates's 13F filing for Q3 2017, filed 30 Oct 2017.